These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 11417349)

  • 1. [Open angle glaucoma: risk factors and progression].
    Kriegeskorte V
    Klin Monbl Augenheilkd; 2001 May; 218(5):A84-6. PubMed ID: 11417349
    [No Abstract]   [Full Text] [Related]  

  • 2. Risk factors for primary open angle glaucoma progression: what we know and what we need to know.
    Rivera JL; Bell NP; Feldman RM
    Curr Opin Ophthalmol; 2008 Mar; 19(2):102-6. PubMed ID: 18301282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of dorzolamide 2% added to timolol maleate 0.5% on intraocular pressure, retrobulbar blood flow, and the progression of visual field damage in patients with primary open-angle glaucoma: a single-center, 4-year, open-label study.
    Martínez A; Sánchez M
    Clin Ther; 2008 Jun; 30(6):1120-34. PubMed ID: 18640468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic antihypertensive medication and incident open-angle glaucoma.
    Müskens RP; de Voogd S; Wolfs RC; Witteman JC; Hofman A; de Jong PT; Stricker BH; Jansonius NM
    Ophthalmology; 2007 Dec; 114(12):2221-6. PubMed ID: 17568677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intercurrent factors associated with the development of open-angle glaucoma in the European glaucoma prevention study.
    Stewart RM; Clearkin LG
    Am J Ophthalmol; 2008 Jan; 145(1):182; author reply 182-3. PubMed ID: 18154757
    [No Abstract]   [Full Text] [Related]  

  • 6. Glaucoma case report: a nutritional response.
    Veach JE
    Optometry; 2003 Dec; 74(12):775-81. PubMed ID: 14677729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical therapy of glaucoma.
    Singh A
    Ophthalmol Clin North Am; 2005 Sep; 18(3):397-408, vi. PubMed ID: 16054997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive factors for progressive optic nerve damage in various types of chronic open-angle glaucoma.
    Martus P; Stroux A; Budde WM; Mardin CY; Korth M; Jonas JB
    Am J Ophthalmol; 2005 Jun; 139(6):999-1009. PubMed ID: 15953429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for glaucoma onset and progression.
    Coleman AL; Miglior S
    Surv Ophthalmol; 2008 Nov; 53 Suppl1():S3-10. PubMed ID: 19038621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pressure fluctuation.
    Caprioli J; Coleman A
    Ophthalmology; 2009 Apr; 116(4):817. PubMed ID: 19344837
    [No Abstract]   [Full Text] [Related]  

  • 11. Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial.
    Bengtsson B; Leske MC; Hyman L; Heijl A;
    Ophthalmology; 2007 Feb; 114(2):205-9. PubMed ID: 17097736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive factors for open-angle glaucoma among patients with ocular hypertension in the European Glaucoma Prevention Study.
    ; Miglior S; Pfeiffer N; Torri V; Zeyen T; Cunha-Vaz J; Adamsons I
    Ophthalmology; 2007 Jan; 114(1):3-9. PubMed ID: 17070596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Low-pressure Glaucoma Treatment Study (LoGTS) study design and baseline characteristics of enrolled patients.
    Krupin T; Liebmann JM; Greenfield DS; Rosenberg LF; Ritch R; Yang JW;
    Ophthalmology; 2005 Mar; 112(3):376-85. PubMed ID: 15745762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Routine reduction of glaucoma medication following phacoemulsification.
    Bowling B; Calladine D
    J Cataract Refract Surg; 2009 Mar; 35(3):406-7; author reply 407. PubMed ID: 19251121
    [No Abstract]   [Full Text] [Related]  

  • 15. Modern alchemy: fixed combinations of glaucoma drugs.
    Katz LJ
    Am J Ophthalmol; 2005 Jul; 140(1):125-6. PubMed ID: 16038653
    [No Abstract]   [Full Text] [Related]  

  • 16. The influence of diclofenac ophthalmic solution on the intraocular pressure-lowering effect of topical 0.5% timolol and 0.005% latanoprost in primary open-angle glaucoma patients.
    Costagliola C; Parmeggiani F; Antinozzi PP; Caccavale A; Cotticelli L; Sebastiani A
    Exp Eye Res; 2005 Nov; 81(5):610-5. PubMed ID: 15949795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early aggressive intraocular pressure lowering, target intraocular pressure, and a novel concept for glaucoma care.
    Singh K; Shrivastava A
    Surv Ophthalmol; 2008 Nov; 53 Suppl1():S33-8. PubMed ID: 19038622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uniocular drug trials.
    Rotchford AP; King AJ
    Ophthalmology; 2004 Dec; 111(12):2315; author reply 2315-6. PubMed ID: 15582097
    [No Abstract]   [Full Text] [Related]  

  • 19. A comparison of the effects of dorzolamide/timolol fixed combination versus latanoprost on intraocular pressure and pulsatile ocular blood flow in primary open-angle glaucoma patients.
    Janulevicienë I; Harris A; Kagemann L; Siesky B; McCranor L
    Acta Ophthalmol Scand; 2004 Dec; 82(6):730-7. PubMed ID: 15606472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uniocular drug trial.
    Jones R; Triana MI; Zaslow K; Sponsel WE
    Ophthalmology; 2005 Jun; 112(6):1170; author reply 1170-1. PubMed ID: 15936449
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.